| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
| Targets |
Angiotensin receptor
|
|---|---|
| ln Vivo |
Angiotensin II 5-valine infusion resulted in a significant increase in systolic blood pressure (SBP) by day 12 (197 ± 7 mm Hg). Losartan may prevent the development of hypertension associated with ANG II infusion. Blood and kidney samples were collected, HPLC was performed to separate angiotensin II 5-valine (exogenous) from Ile5-ANG II (endogenous), and the fractions were measured by radioimmunoassay. In the angiotensin II 5-valine infusion construct that received losartan treatment, total ANG II levels increased to a greater extent than in the waveform that did not receive lossartan treatment (289 ± 20 v 119 ± 14 fmol/ mL). However, Losartan significantly reduced the enhancement of renal Val5-ANG II content by 88%, and this enhancement occurred only in the specific gravity of Val5-ANG II [1].
|
| References | |
| Additional Infomation |
Val(5)-angiotensin II is an angiotensin II.
|
| Molecular Formula |
C51H73N13O14
|
|---|---|
| Molecular Weight |
1092.222
|
| Exact Mass |
1031.518
|
| Elemental Analysis |
C, 56.08; H, 6.74; N, 16.67; O, 20.51
|
| CAS # |
58-49-1
|
| PubChem CID |
9811952
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.77
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
28
|
| Heavy Atom Count |
74
|
| Complexity |
1960
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
NC(NCCC[C@H](NC([C@@H](N)CC(O)=O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CC1=CC=C(O)C=C1)C(N[C@@H](C(C)C)C(N[C@@H](CC1=CN=CN1)C(N1[C@H](C(N[C@@H](CC2=CC=CC=C2)C(O)=O)=O)CCC1)=O)=O)=O)=O)=O)=N.CC(O)=O
|
| InChi Key |
JVCJXRGXGITABA-IAQGTVMASA-N
|
| InChi Code |
InChI=1S/C49H69N13O12.C2H4O2/c1-26(2)39(60-42(67)33(12-8-18-54-49(51)52)56-41(66)32(50)23-38(64)65)45(70)57-34(20-29-14-16-31(63)17-15-29)43(68)61-40(27(3)4)46(71)58-35(22-30-24-53-25-55-30)47(72)62-19-9-13-37(62)44(69)59-36(48(73)74)21-28-10-6-5-7-11-28;1-2(3)4/h5-7,10-11,14-17,24-27,32-37,39-40,63H,8-9,12-13,18-23,50H2,1-4H3,(H,53,55)(H,56,66)(H,57,70)(H,58,71)(H,59,69)(H,60,67)(H,61,68)(H,64,65)(H,73,74)(H4,51,52,54);1H3,(H,3,4)/t32-,33-,34-,35-,36-,37-,39-,40-;/m0./s1
|
| Chemical Name |
(2S,5S,8S,11S,14S,17S)-2-((1H-imidazol-4-yl)methyl)-17-amino-1-((S)-2-(((S)-1-carboxy-2-phenylethyl)carbamoyl)pyrrolidin-1-yl)-14-(3-guanidinopropyl)-8-(4-hydroxybenzyl)-5,11-diisopropyl-1,4,7,10,13,16-hexaoxo-3,6,9,12,15-pentaazanonadecan-19-oic acid compound with acetic acid (1:1)
|
| Synonyms |
Human Angiotensin II Acetate Salt; Val5-ANG II; H-Asp-Arg-Val-Tyr-Val-His-Pro-Phe-OH; Angiotensin acetate; (Val5)-Angiotensin II
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ~100 mg/mL (~96.9 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 33.33 mg/mL (32.29 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9156 mL | 4.5778 mL | 9.1557 mL | |
| 5 mM | 0.1831 mL | 0.9156 mL | 1.8311 mL | |
| 10 mM | 0.0916 mL | 0.4578 mL | 0.9156 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00910923 | Completed | Drug: JNJ-38431055 | Diabetes Mellitus, Type 2 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
November 2008 | Phase 1 |
| NCT01054118 | Completed | Drug: JNJ-38431055 Drug: Sitagliptin 100 mg |
Diabetes Mellitus, Type 2 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
December 2009 | Phase 1 |
| NCT00871507 | Completed | Drug: JNJ-38431055 Dose 2 Drug: JNJ-38431055 Dose 1 |
Diabetes Mellitus, Type 2 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
April 2009 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
